New Zealand - English - Medsafe (Medicines Safety Authority)
Page 1 of 4
NEW ZEALAND CONSUMER MEDICINE INFORMATION
modified release capsules 160mg
What is in this leaflet
This leaflet answers some common
questions about CARDINOL LA.
It does not contain all the available
information. It does not take the
place of talking to your doctor or
All medicines have risks and
benefits. Your doctor has weighed
the risks of you using this medicine
against the benefits they expect it
will have for you.
If you have any concerns about
taking this medicine, ask your
doctor or pharmacist.
Keep this leaflet with the
medicine. You may need to read it
What CARDINOL LA
is used for
CARDINOL LA capsules contain the
active ingredient propranolol
hydrochloride, which belongs to a
group of medicines called beta-
blockers. These medicines work by
changing the body's response to
some nerve impulses, especially in
CARDINOL LA is used to lower
blood pressure, help in the
prevention of chest pain (angina)
and for the long-term prevention of
future heart attacks.
Ask your doctor if you have any
questions about why this
medicine has been prescribed for
Your doctor may have prescribe it
for another reason.
There is no evidence that
CARDINOL LA is addictive.
This medicine is available only with
a doctor’s prescription.
CARDINOL LA is not recommended
for use in children.
Before you take
When you must not take
Do not take CARDINOL LA if you
have an allergy to:
any of the ingredients listed at
the end of this leaflet
any other similar medicines such
Symptoms of an allergic reaction
may include: shortness of breath;
wheezing or difficulty breathing;
swelling of the face, lips, tongue or
other parts of the body; rash, itching
or hives on the skin.
Do not take CARDINOL LA if you
asthma or severe breathing
heart problems such as, heart
failure, low blood pressure,
problems with your circulation,
Prinzmetal’s angina or a slow
low blood sugar levels
Do not take this medicine after
the expiry date printed on the
pack or if the packaging is torn or
shows signs of tampering.
If it has expired or is damaged,
return it to your pharmacist for
If you are not sure whether you
should start taking this medicine,
talk to your doctor.
Before you take it
Tell your doctor if you have
allergies to any other medicines,
foods, preservatives or dyes.
Tell your doctor if you have or
have had any of the following
asthma or serious breathing
low blood pressure
problems with your circulation
diabetes or low blood sugar
an overactive thyroid gland
Tell your doctor if you are fasting
or have been fasting recently.
Tell your doctor if you plan to
Tell your doctor if you are
pregnant or plan to become
pregnant or are breast-feeding.
Your doctor can discuss with you
the risks and benefits involved.
If you have not told your doctor
about any of the above, tell
him/her before you start taking
Taking other medicines
Tell your doctor or pharmacist if
you are taking any other
medicines, including any that you
get without a prescription from
your pharmacy, supermarket or
health food shop.
Medicines that may interfere with
CARDINOL LA include:
insulin and other medications
used to treat diabetes
medicines used in the treatment
and prevention of migraines
such as ergotamine and
ergotamine type compounds, or
medicines used to treat angina
or an irregular heartbeat, e.g.
Page 2 of 4
nifedipine, clonidine, quinidine,
calcium channel blockers e.g.
verapamil, diltiazem, medicines
used to treat high blood pressure
digoxin, a medicine used to treat
lidocaine, a local anaesthetic
sympathomimetic agents e.g.
adrenalin (used in emergency
hydralazine, a medicine used to
relax and widen blood vessels
cimetidine, a medicine
commonly used to treat reflux
medicines used to treat pain or
inflammation such as ibuprofen
chlorpromazine and thioridazine,
medicines used to treat
warfarin, a medicine used to
prevent blood clots
theophylline, a medicine used to
rifampicin, an antibiotic
These medicines may be affected
by CARDINOL LA or may affect
how well CARDINOL LA works.
You may need different amounts of
your medicines or you may need to
take different medicines.
Your doctor or pharmacist has more
information on medicines to be
careful with or avoid while taking
How to take
Follow all directions given to you
by your doctor or pharmacist
They may differ from the information
contained in this leaflet.
If you do not understand the
instructions on the bottle, ask
your doctor or pharmacist for
How much to take
Your doctor will tell you how much
CARDINOL LA you need to take
It is important that you take
CARDINOL LA as directed by your
doctor. Do not take more than the
The usual starting dose of
CARDINOL LA for high blood
pressure and chest pain is one
capsule daily, taken either in the
morning or evening.
For the prevention of further heart
attacks the treatment will usually
begin between 5 and 21 days
following the heart attack. The usual
dose for prevention of further heart
attacks is usually one 40mg tablet,
four times a day for around two to
three days. This dose may be given
as one capsule of CARDINOL LA
How to take it
Swallow the capsule whole with a
full glass of water.
How long to take it
Continue taking your medicine
for as long as your doctor tells
This medicine helps to control your
condition, but does not cure it. It is
important to keep taking your
medicine even if you feel well.
If you stop taking your medicine
suddenly, it may worsen your chest
pain (angina) or cause other heart
complications to occur. Your doctor
may want you to gradually reduce
the amount of CARDINOL LA you
are taking before stopping
If you forget a dose
If you forget a dose, just take the
next dose when it is due. Do not
take more than one dose at a
time to make up for missed
Taking your medicine at the same
time each day may help you to
remember to take it regularly. If you
have trouble remembering to take
your medicine, ask you pharmacist
for some hints.
If you take too much
Immediately telephone your
doctor or the National Poisons
Information Centre (0800 POISON
or 0800 764 766) for advice, or go
to Accident and Emergency at
the nearest hospital, if you think
that you or anyone else may have
taken too much CARDINOL LA.
Do this even if there are no signs
of discomfort or poisoning. You
may need urgent medical attention.
Symptoms of an overdose may
include fatigue, dizziness,
weakness, fainting, irregular
heartbeat and difficulty breathing.
While you are taking
Things you must do
Tell all doctors, dentists and
pharmacists who are treating you
that you are taking CARDINOL
Tell your doctor or pharmacist
that you are taking CARDINOL LA
before you start any new
If you become pregnant while
taking CARDINOL LA, tell your
If you are going to have a
surgery, tell the surgeon or
anaesthetist that you are taking
It may affect other medicines used
If you are going to have any
blood tests, tell your doctor that
you are taking CARDINOL LA.
It may interfere with the results of
If you are being treated for diabetes,
make sure you check your blood
sugar level regularly. CARDINOL
LA may affect how well your
diabetes is controlled. It may also
cover up some of the symptoms of
low blood sugar (also called
hypoglycaemia) such as a fast
heartbeat. CARDINOL LA may also
make an episode of low blood sugar
last longer. Your doctor may need
to adjust the dose of your insulin or
Things you must not do
Page 3 of 4
Do not take CARDINOL LA to
treat any other complaints unless
your doctor tells you to.
Do not give this medicine to
anyone else, even if they have
the same condition as you.
Do not stop taking your medicine
or lower the dose without
checking with your doctor.
Things to be careful of
Be careful driving or operating
machinery until you know how
CARDINOL LA affects you.
This medicine may cause dizziness
or tiredness in some people. If you
have any of these symptoms, do not
drive, operate machinery or do
anything else that could be
Be careful when drinking alcohol
while you are taking this
If you drink alcohol, dizziness or
light-headedness may be worse.
If you feel light-headed, dizzy or
faint when getting out of bed or
standing up, get up slowly.
Standing up slowly, especially when
you get up from bed or chairs, will
help your body get used to the
change in position and blood
pressure. If this problem continues
or gets worse, talk to your doctor.
Tell your pharmacist or doctor as
soon as possible if you do not
feel well while you are taking
All medicines can have some
unwanted effects. Sometimes they
are serious, most of the time they
are not. You may need medical
treatment if you get some of the
Do not be alarmed by this list of
possible side effects. You may
not experience any of them.
Ask your doctor or pharmacist to
answer any questions you may
Tell your doctor or pharmacist if
you notice any of the following
and they worry you:
dizziness, lightheadedness or
fainting, especially when you get
sleep disturbances or
mood changes or confusion
feeling sick (nausea), vomiting,
diarrhoea, stomach pain
cold fingers and toes
numbness and spasm in the
fingers which is followed by
warmth and pain (Raynaud’s
These are the mild side effects of
Tell your doctor immediately if
you notice any of the following:
irritated eyes, blurred vision
signs of low blood sugar
(hypoglycaemia) such as
sweating, weakness, hunger,
dizziness, trembling, headache,
flushing or paleness, numbness
seizure linked to low blood sugar
changes to mood
These are serious side effects. You
may need urgent medical attention.
Serious side effects are rare.
Tell your doctor immediately or
got to Accident and Emergency
at the nearest hospital if you
notice any of the following:
swelling of the face, lips, tongue
or throat which may cause
difficulty in swallowing
chest tightness, difficulty
fast, slow or irregular heart beat
bruising or bleeding more easily
signs of frequent infection such
as fever, chills, sore throat and
shortness of breath (sometimes
with tiredness, weakness and
reduced ability to exercise),
which may occur together with
swelling of the feet or legs due to
These are very serious side effects.
If you have them, you may have
had a serious allergic reaction to
CARDINOL LA. You may need
urgent medical attention or
All of these side effects are very
Tell your doctor or pharmacist if
you notice anything that is
making you feel unwell.
Other side effects not listed above
may also occur in some people.
Some of these side effects, for
example, changes to platelets or
antibodies in the blood, can only be
found when your doctor does tests
from time to time to check your
Keep your capsules in the bottle
until it is time to take them.
If you take the capsules out of the
bottle they may not keep well.
Keep your capsules in a cool dry
place where the temperature
stays below 25°C.
Do not store CARDINOL LA or any
other medicine in the bathroom or
near a sink. Do not leave it on a
window sill or in the car.
Heat and dampness can destroy
Keep it where children cannot
A locked cupboard at least one-and-
a half metres above the ground is a
good place to store medicines.
If your doctor tells you to stop
taking this medicine or the expiry
date has passed, ask your
pharmacist what to do with any
medicine that is left over.
Page 4 of 4
What CARDINOL LA
capsules look like
CARDINOL LA 160mg capsules are
half clear and half green coloured
capsules containing cream and
white coloured pellets.
Each CARDINOL LA capsule
contains the active ingredient,
Each CARDINOL LA 160mg
capsule also contains the
ingredients sucrose, maize starch,
shellac, talc and the gelatin capsule.
CARDINOL LA 160 mg does not
contain gluten or lactose.
If you want to know
Should you have any questions
regarding this product, please
contact your doctor or pharmacist.
Who supplies this
Distributed in New Zealand by:
Mylan New Zealand Ltd,
PO Box 11183,
Telephone: (09) 579 2792
Date of information
08 January 2018
(Based on datasheet dated 08
January 2018 )
Page 1 of 9
NEW ZEALAND DATA SHEET
1. Product Name
CARDINOL LA, 160mg, modified release capsule.
2. Qualitative and Quantitative Composition
Each modified release capsule contains 160mg of propranolol hydrochloride BP.
For the full list of excipients, see section 6.1.
3. Pharmaceutical Form
CARDINOL LA is presented as size 1 gelatin capsules with a clear colourless body and opaque,
green cap containing cream and white pellets.
CARDINOL LA capsules contain spheroids of
the beta-blocker propranolol hydrochloride which
have a sustained release coating to provide long action.
4. Clinical Particulars
CARDINOL LA is indicated for the following:
Control of hypertension.
Management of agina pectoris.
Long term prophylaxis after recovery from acute myocardial infarction.
Dose and method of administration
The starting dose is one capsule daily, taken either morning or evening. An adequate response is
seen in most patients at this dosage. If necessary, it can be increased to two capsules and a
further reduction in blood pressure can be attained if a diuretic or other antihypertensive agent is
given in addition to CARDINOL LA.
An adequate response is usually obtained with one capsule daily either morning or evening,
dependant on patient convenience.
Post Myocardial infarction
Page 2 of 9
Treatment should start between days 5 and 21 after myocardial infarction with one 40 mg
propranolol tablet four times a day for 2 or 3 days.
In order to achieve maximum compliance,
the total daily dosage of 160 mg propranolol may
thereafter be given as a single CARDINOL LA capsule. Compliance is extremely important as
beta-blockade may have to be continued indefinitely.
Evidence concerning the relation between blood level and age is conflicting. With regard to the
elderly, the optimum dose should be individually determined according to clinical response.
CARDINOL LA is not recommended for use in children.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
CARDINOL LA must not be used if there is a history of bronchial asthma or bronchospasm
Bronchospasm can usually be reversed by beta
agonist bronchodilators such as salbutamol.
Large doses of the beta
agonist bronchodilator may be required to overcome the beta blockade
produced by propranolol and the dose should be titrated according to the clinical response; both
Glucagon (1 to 2 mg given intravenously) has also been reported to produce a bronchodilator
effect in asthmatic patients. Oxygen or artificial ventilation may be required in severe cases.
CARDINOL LA as with other beta-blockers must not be used in patients with any of the following
conditions: known hypersensitivity to the substance; bradycardia; cardiogenic shock; hypotension;
metabolic acidosis; after prolonged fasting; severe peripheral arterial circulatory disturbances;
uncontrolled heart failure; Prinzmetal’s angina.
CARDINOL LA must not be used in patients prone to hypoglycaemia, i.e., patients after prolonged
fasting or patients with restricted counter-regulatory reserves. Patients with restricted counter-
regulatory reserves may have reduced autonomic and hormonal responses to hypoglycaemia
which includes glycogenolysis, gluconeogenesis and/or impaired modulation of insulin secretion.
Patients at risk for an inadequate response to hypoglycaemia includes individuals with malnutrition,
prolonged fasting, starvation, chronic liver disease, diabetes and concomitant use of drugs which
block the full response to catecholamines.
Special warnings and precautions for use
Propranolol as with other beta-blockers:
although contraindicated in uncontrolled heart failure, may be used in patients whose signs
of heart failure have been controlled. Caution must be exercised in patients whose cardiac
reserve is poor.
should not be used in combination with calcium channel blockers with negative inotropic
effects (e.g. verapamil, diltiazem), as it can lead to an exaggeration of these effects
particularly in patients with impaired ventricular function and/or SA or AV conduction
abnormalities. This may result in severe hypotension, bradycardia and cardiac failure.
intravenously within 48 hours of discontinuing the other.
Page 3 of 9
should not be used in patients with Prinzmetal’s angina and beta
selective agents should
be used with care.
although contraindicated in severe peripheral arterial circulatory disturbances, may also
aggravate less severe peripheral arterial circulatory disturbances.
due to its negative effect on conduction time, caution must be exercised if propranolol is
given to patients with first degree heart block.
may block/modify the signs and symptoms of hypoglycaemia (especially tachycardia).
neonates, infants, children, elderly patients, patients on haemodialysis or patients suffering
from chronic liver disease and patients suffering from overdose. Severe hypoglycaemia
associated with propranolol long-acting has rarely presented with seizures and/or coma in
isolated patients. Caution must be exercised in the concurrent use of propranolol and
hypoglycaemic therapy in diabetic patients. Propranolol may prolong the hypoglycaemic
response to insulin.
may mask the signs of thyrotoxicosis.
phaeochromocytoma, an alpha-blocker may be given concomitantly.
will reduce heart rate as a result of its pharmacological action. In the rare instances when a
treated patient develops symptoms that may be attributable to a slow heart rate, the dose
may be reduced.
may cause a more severe reaction to a variety of allergens when given to patients with a
history of anaphylactic reaction to such allergens. Such patients may be unresponsive to
the usual doses of adrenaline used to treat the allergic reactions.
Abrupt withdrawal of beta-blockers is to be avoided. The dosage should be withdrawn gradually
over a period of 7 to 14 days. An equivalent dosage of another beta-blocker may be substituted
during the withdrawal period to facilitate a reduction in dosage below CARDINOL LA 160 mg.
Patients should be followed during withdrawal especially those with ischaemic heart disease.
When a patient is scheduled for surgery and a decision is made to discontinue beta-blocker
therapy, this should be done at least 24 hours prior to the procedure. The risk/benefit of stopping
beta blockade should be made for each patient.
Since the half-life may be increased in patients with significant hepatic or renal impairment, caution
must be exercised when starting treatment and selecting the initial dose.
Propranolol must be used with caution in patients with decompensated cirrhosis.
In patients with portal hypertension, liver function may deteriorate and hepatic encephalopathy may
develop. There have been reports suggesting that treatment with propranolol may increase the risk
of developing hepatic encephalopathy.
Interference with laboratory tests: Propranolol has been reported to interfere with the estimation
of serum bilirubin by the diazo method and with the determination of catecholamines by methods
Interaction with other medicines and other forms of interaction
Propranolol may prolong the hypoglycaemic response to insulin.
Page 4 of 9
Simultaneous administration of rizatriptan and propranolol can cause an increased rizatriptan AUC
by approximately 70 - 80%. The increased rizatriptan exposure is presumed to be caused
by inhibition of first-passage metabolism of rizatriptan through inhibition of monoamine oxidase-A.
If both drugs are to be used, a rizatriptan dose of 5 mg has been recommended.
Class I anti-arrhythmic drugs (e.g. disopyramide) and amiodarone may have potentiating effect on
atrial-conduction time and induce negative inotropic effect.
Digitalis glycosides in association with beta blockers may increase atrioventricular conduction time.
Combined use of beta-blockers and calcium channel blockers with negative inotropic effects (e.g.
verapamil, diltiazem) can lead to an exaggeration of these effects particularly in patients with
impaired ventricular function and/or sino-atrial or atrio-ventricular conduction abnormalities. This
may result in severe hypotension, bradycardia and cardiac failure. Neither the beta-blocker nor the
calcium channel blocker should be administered intravenously within 48 hours of discontinuing the
Concomitant therapy with dihydropyridine calcium channel blockers e.g. nifedipine, may increase
the risk of hypotension, and cardiac failure may occur in patients with latent cardiac insufficiency.
Concomitant use of sympathomimetic agents e.g. adrenaline, may counteract the effect of beta-
blockers. Caution must be exercised in the parenteral administration of preparations containing
adrenaline to patients taking beta-blockers as, in rare cases, vasoconstriction, hypertension and
bradycardia may result.
Administration of propranolol during infusion of lignocaine may increase the plasma concentration
of lignocaine by about 30%. Patients already receiving propranolol tend to have higher lignocaine
levels than controls. The combination should be avoided.
Concomitant use of cimetidine or hydralazine will increase plasma levels of propranolol, and
concomitant use of alcohol may increase the plasma levels of propranolol.
Beta-blockers may exacerbate the rebound hypertension which can follow the withdrawal of
clonidine. If the two medicines are co-administered, the beta-blocker should be withdrawn several
days before discontinuing clonidine. If replacing clonidine by beta-blocker therapy, the introduction
of beta-blockers should be delayed for several days after clonidine administration has stopped.
Caution must be exercised if ergotamine, dihydroergotamine or related compounds are given in
combination with propranolol since vasospastic reactions have been reported in a few patients.
Concomitant use of prostaglandin synthetase inhibiting medicines e.g. ibuprofen and indometacin,
may decrease the hypotensive effects of propranolol.
Concomitant administration of propranolol and chlorpromazine may result in an increase in plasma
levels of both medicines. This may lead to an enhanced antipsychotic effect for chlorpromazine
and an increased antihypertensive effect for propranolol.
Caution must be exercised when using anaesthetic agents with propranolol. The anaesthetist
should be informed and the choice of anaesthetic should be an agent with as little negative
inotropic activity as possible. Use of beta-blockers with anaesthetic drugs may result in attenuation
of the reflex tachycardia and increase the risk of hypotension. Anaesthetic agents causing
myocardial depression are best avoided.
Pharmacokinetic studies have shown that the following agents may interact with propranolol due to
effects on the enzyme systems in the liver which metabolise propranolol and these agents:
quinidine, propafenone, rifampicin, theophylline, warfarin, thioridazine, and dihydropyridine calcium
channel blockers such as nifedipine, nisoldipine, nicardipine, isradipine and lacidipine. Owing to
the fact that blood concentrations of either agent may be affected, dosage adjustments may be
Page 5 of 9
needed according to clinical judgement (see also the interaction above concerning concomitant
therapy with dihydropyridine calcium channel blockers).
Fertility, pregnancy and lactation
As with all other medicines, propranolol should not be given in pregnancy unless its use is
essential. There is no evidence of teratogenicity with propranolol. However, beta-blockers reduce
placental perfusion, which may result in intra-uterine foetal death, immature and premature
deliveries. In addition, adverse effects (especially hypoglycaemia and bradycardia in the neonate
and bradycardia in the foetus) may occur. There is an increased risk of cardiac and pulmonary
complications in the neonate in the post-natal period.
Most beta-blockers, particularly lipophilic compounds, will pass into breast milk although to a
variable extent. Breast feeding is therefore not recommended following administration of these
No data available.
Effects on ability to drive and use machines
The use of
propranolol is unlikely to result in any impairment of the ability of patients to drive or
operate machinery. However it should be taken into account that occasionally dizziness or fatigue
Propranolol is usually well tolerated. In clinical studies, the undesired events reported are usually
attributable to the pharmacological actions of propranolol.
The following undesired events, listed by body system, have been reported. The following
definitions of frequencies are used:
(≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available
System Organ class
Blood and lymphatic
Hypoglycaemia in neonates, infants, children, elderly
prolonged fasting and patients with chronic liver disease
has been reported, seizure linked to hypoglycaemia
Sleep disturbances, nightmares
confusion, memory loss, paraesthesia
Page 6 of 9
Discontinuance of the medicine should be considered if, according to clinical judgement, the well-
being of the patient is adversely affected by any of the above reactions. Cessation of therapy with
a beta-blocker should be gradual. In the rare event of intolerance, manifested as bradycardia and
hypotension, the medicine should be withdrawn and, if necessary, treatment for overdosage
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicine is important. It allows
continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are
asked to report any suspected adverse reactions https://nzphvc.otago.ac.nz/reporting/
The symptoms of overdosage may include bradycardia, hypotension, acute cardiac insufficiency
General treatment should include: close supervision, treatment in an intensive care ward, the use
of gastric lavage, activated charcoal and a laxative to prevent absorption of any medicine still
syndrome or exacerbation of myasthenia gravis
have been reported
Dry eyes, visual disturbances
deterioration, precipitation of heart
Respiratory, thoracic and
complaints, sometimes with fatal outcome
exacerbation of psoriasis, skin rashes
Fatigue and/or lassitude (often transient)
An increase in ANA (Antinuclear Antibodies) has
been observed, however, the clinical relevance of
this is not clear
Page 7 of 9
present in the gastrointestinal tract, the use of plasma or plasma substitutes to treat hypotension
Excessive bradycardia can be countered with atropine 1 to 2 mg intravenously and/or a cardiac
pacemaker. If necessary, this may be followed by a bolus dose of glucagon 10 mg intravenously. If
required, this may be repeated or followed by an intravenous infusion of glucagon 1 to 10 mg/hour
depending on response. If no response to glucagon occurs or if glucagon is unavailable,
adrenoceptor stimulant such as dobutamine 2.5 to 10 micrograms/kg/minute by intravenous
infusion may be given.
Dobutamine, because of its positive inotropic effect could also be used to treat hypotension and
acute cardiac insufficiency. It is likely that these doses would be inadequate to reverse the cardiac
effects of beta blockade if a large overdose has been taken. The dose of dobutamine should
therefore be increased if necessary to achieve the required response according to the clinical
condition of the patient.
For further advice on management of overdose please contact the National Poisons Information
Centre (0800 POISON or 0800 764 766).
5. Pharmacological Properties
Pharmacotherapeutic group: beta blocking agents, ATC code: C07AA05
Mechanism of action
Propranolol is a competitive antagonist at both the beta
-adrenoceptors. It has no
agonist activity at the beta-adrenoceptor, but has membrane stabilising activity at concentrations
exceeding 1 to 3 mg/litre, though such concentrations are rarely achieved during oral therapy.
Competitive beta blockade has been demonstrated in man by a parallel shift to the right in the
dose-heart rate response curve to beta-agonists such as isoprenaline.
contraindicated in uncontrolled heart failure.
Propranolol is a racemic mixture and the active form is the S (-) isomer. With the exception of
inhibition of the conversion of thyroxine to triiodothyronine it is unlikely that any additional ancillary
properties possessed by R (+) propranolol, in comparison with the racemic mixture will give rise to
different therapeutic effects.
Clinical efficacy and safety
Propranolol is effective and well-tolerated in most ethnic populations, although the response may
be less in black patients.
The sustained release preparation of propranolol maintains a higher degree of beta
hours after dosing compared with conventional propranolol.
Propranolol is completely absorbed after oral administration and peak plasma concentrations occur
1 to 2 hours after dosing in fasting patients. Following oral dosing with the sustained release
preparation of propranolol the blood profile is flatter than after conventional propranolol but the
half-life is increased to between 10 and 20 hours.
Page 8 of 9
Propranolol is widely and rapidly distributed throughout the body with highest levels occurring in
the lungs, liver, kidney, brain and heart. Propranolol is highly protein bound (80 to 95%).
The liver removes up to 90% of an oral dose with an elimination half-life of 3 to 6 hours.
Preclinical safety data
Propranolol is a drug where there is an extensive clinical
experience has been obtained. Relevant information for the
List of excipients
Sucrose, maize starch, talc, shellac and gelatin capsule.
CARDINOL LA is gluten and lactose free.
Blister pack: 2 years.
Bottle pack: 2 years.
Special precautions for storage
Blister pack: store at or below 30°C.
Bottle pack: store at or below 25°C.
Nature and contents of container
Blister pack of 30 capsules.
HDPE bottle with a tamper evident PP cap. Pack-size of 100 capsules.
Not all pack types and sizes may be marketed.
Special precautions for disposal
7. Medicines Schedule
8. Sponsor Details
Mylan New Zealand Ltd
PO Box 11183
Page 9 of 9
9. Date of First Approval
22 February 1984
10. Date of Revision of the Text
08 January 2018 Revised to SmPC format. Shelf-life reduction to 2 years for the bottle pack.